share_log

YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings May Just Be The Starting Point

YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings May Just Be The Starting Point

宜昌HEC長江藥業(HKG: 1558)的收益可能只是起點
Simply Wall St ·  05/02 20:19

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholders.

宜昌東方長江藥業有限公司's(HKG: 1558)強勁的收益報告獲得了股價的積極走勢的回報。我們的分析發現了更多我們認爲對股東有利的因素。

earnings-and-revenue-history
SEHK:1558 Earnings and Revenue History May 3rd 2024
SEHK: 1558 收益和收入歷史記錄 2024 年 5 月 3 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

For anyone who wants to understand YiChang HEC ChangJiang Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥482m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If YiChang HEC ChangJiang Pharmaceutical doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

對於任何想了解宜昌HEC長江藥業超出法定數字的利潤的人來說,值得注意的是,在過去的十二個月中,由於異常項目,法定利潤減少了4.82億元人民幣。看到不尋常的項目使公司利潤付出代價從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。鑑於這些單列項目被認爲不尋常,這並不奇怪。如果宜昌HEC長江藥業沒有看到這些不尋常的支出重演,那麼在其他條件相同的情況下,我們預計其利潤將在來年增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On YiChang HEC ChangJiang Pharmaceutical's Profit Performance

我們對宜昌東芝長江藥業盈利表現的看法

Because unusual items detracted from YiChang HEC ChangJiang Pharmaceutical's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that YiChang HEC ChangJiang Pharmaceutical's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at an extremely impressive rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for YiChang HEC ChangJiang Pharmaceutical and you'll want to know about this.

由於不尋常的項目削弱了宜昌東方長江藥業去年的收益,你可能會爭辯說,我們可以預期本季度的業績會有所改善。基於這一觀察,我們認爲宜昌東方長江藥業的法定利潤實際上可能低估了其盈利潛力!最重要的是,其每股收益在過去一年中以極其驚人的速度增長。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。你可能會有興趣知道,我們發現了宜昌東方長江藥業的1個警告信號,你會想知道的。

Today we've zoomed in on a single data point to better understand the nature of YiChang HEC ChangJiang Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單一數據點,以更好地了解宜昌HEC長江藥業利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論